Atypical endometrial hyperplasia
Information
- Disease name
- Atypical endometrial hyperplasia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03671811 | Active, not recruiting | Phase 2 | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | January 21, 2019 | November 7, 2024 |
| NCT02397083 | Active, not recruiting | Phase 2 | Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer | September 23, 2015 | September 30, 2026 |
| NCT00788671 | Active, not recruiting | Phase 2 | Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer | November 3, 2008 | November 30, 2024 |
| NCT00892866 | Active, not recruiting | N/A | CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells | April 13, 2009 | May 31, 2025 |
| NCT00483327 | Completed | Phase 2 | Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate | June 2007 | October 2013 |
| NCT00490087 | Completed | Phase 3 | Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women | January 1999 | March 2007 |
| NCT03241888 | Completed | Phase 2/Phase 3 | Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia | July 4, 2017 | June 18, 2020 |
| NCT04385667 | Completed | Phase 2/Phase 3 | LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia | May 20, 2020 | December 25, 2022 |
| NCT04491682 | Completed | Phase 2/Phase 3 | Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia | September 1, 2020 | June 20, 2022 |
| NCT06379113 | Recruiting | Phase 2/Phase 3 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | July 13, 2022 | March 30, 2025 |
| NCT06390904 | Recruiting | Phase 2/Phase 3 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients | July 13, 2022 | June 30, 2025 |
| NCT05647109 | Recruiting | Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer | September 1, 2021 | October 31, 2025 | |
| NCT05675787 | Recruiting | Phase 2 | Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia | January 6, 2023 | October 31, 2025 |
| NCT03463252 | Recruiting | Phase 2/Phase 3 | Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC | April 1, 2018 | December 30, 2030 |
| NCT05051722 | Recruiting | Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | August 3, 2021 | December 30, 2025 | |
| NCT05172999 | Recruiting | Phase 2/Phase 3 | Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia | January 8, 2022 | June 30, 2026 |
| NCT05316493 | Recruiting | Phase 2/Phase 3 | Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia | June 13, 2022 | February 28, 2026 |
| NCT05316935 | Recruiting | Phase 2/Phase 3 | GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | July 13, 2022 | March 30, 2025 |
| NCT04607252 | Terminated | Phase 2/Phase 3 | Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia | January 11, 2021 | June 3, 2021 |
| NCT04683237 | Withdrawn | Phase 2/Phase 3 | Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia | March 20, 2021 | November 30, 2024 |
| NCT01943058 | Withdrawn | Phase 2 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | March 2014 | October 2017 |
- MedGen concept unique identifier (MedGen Concept name)
- C0349579
- MedGen unique identifier (MedGen Concept name)
- 138105